Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Asthma cost-effectiveness

Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJ, Pedersen SE, Bateman ED. GOAL Investigators Group. Cost-effectiveness of asthma control an economic appraisal of the GOAL study. Allergy 2006 61(5) 531-6. [Pg.655]

Lahdensuo A, Haahtela T, Herrala J, et al Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland. BMJ 1998 316 1138-1139. (Ib)... [Pg.176]

Trautner C, Richter B, Berger M Cost effectiveness of a structural treatment and teaching program on asthma. Eur Respir 1993 6 1485-1491. [Pg.178]

Sullivan S, Elixhauser A, Buist AS, Luce BR, Eisenberg J, Weiss KB National Asthma Education and Prevention Program Working Group Report on the cost effectiveness of asthma care. Am J Respir Crit Care Med 1996 154(3 pt 2) S84-S95. [Pg.179]

Various health economic analysis strategies are available to assist in exploring the value of allergy and asthma preventions. Of the various strategies, cost-effectiveness analysis is becoming the leading method. [Pg.186]

Sullivan SD, Buxton M, Andersson LF, Lamm CJ, Liljas B, Chen YZ, Pauwels RA, Weiss KB Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003 112 1229-1236. (II)... [Pg.191]

Sullivan SD, Weiss KB Assessing cost-effectiveness in asthma care Building an economic model to study the impact of alternative intervention strategies. Allergy 1993 47 146-152. (NC)... [Pg.192]

Liljas B, Lahdensuo A Is asthma self-management cost-effective (review) Patient Educ Couns 1997 32 S97-S104. (NC)... [Pg.192]

Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, Kuntz KM Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma Results from the asthma policy model. J Allergy Clin Immunol 2001 108 39-49. (NC)... [Pg.192]

Some controversy exists concerning the most cost-effective delivery system (MDI plus holding chamber versus nebulization) to be used in treating severe acute asthma in the emergency department and hospital (see below). The DPIs are currently not indicated for the treatment of severe acute asthma exacerbations. Patients with more severe obstruction may not be able to generate sufficient peak inspiratory flows for adequate delivery. ... [Pg.519]

Numerous studies have shown that the inhaled /32-agonists administered by MDI plus holding chamber provide a similar outcome in severe acute asthma as administration by jet nebulizers. Proponents of administration by MDI plus holding chambers argue that it is more cost-effective and so should replace nebulizer therapy. However, appropriate cost analyses have yet to be performedNor have there been comparisons in the most severe subsets, where combination therapy and continuous nebulization are recommended. Current practice should be based on the comfort level of the clinical staff until sufficient data are available to warrant a wholesale recommendation of one method. [Pg.523]

The NAEPP recommendations provide numerous alternatives for long-term controllers in mild to moderate persistent asthma, and few studies have compared their relative cost-effectiveness. This is important because outside the realm of randomized clinical trials that... [Pg.532]

Lord J, Ducharme FM, Stamp RJ, et al. Cost-effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma. Br Med J 1999 319 1470-1471. [Pg.534]

Rutten-van Molken M, Vandoorslaer EKA, Jansen MCC, Vanessenzandvliet EE, Rutten FFH (1993) Cost-effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. Pharmacoeconomics 4 257-270. [Pg.430]

Several studies have performed an economic evaluation of the different methods to deliver aerosolized drugs in hospitalized patients (113). Conversely, data on efficacy and cost-effectiveness of two equivalent treatments, administered via different devices to outpatients with asthma are scarce. Efficacy, measured as the total number of exacerbations, days with exacerbations and hospitalizations, and healthcare utilization were measured over a period of 52 weeks in 445 patients, treated either via pMDI or via Turbuhaler in Canada (114). In this study, effectiveness of treatment and cost differences were in favor of the DPI. [Pg.162]

Liljas B, Stahl E, Pauwels RA. Cost-effectiveness analysis of a dry powder inhaler (Turbuhaler) versus a pressurised metered dose inhaler in patients with asthma. Pharmacoeconomics 1997 12 267-277. [Pg.171]

Stallberg B, Ekstrom T, Neij F, Olsson P, Skoogh BE, Wennergren G, Lofdahl CG. SHARE Trial Group. A real-life cost-effectiveness evaluation of budesonide/ formoterol maintenance and reliever therapy in asthma. Respir Med 2008 102(10) 1360-70. [Pg.373]

O Connor JFB, Singer ME, Richter JE. The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma. Am J Gastroenterol 1999 94 1472-1480. [Pg.440]

More research is needed to determine the cause of the rapid increase in childhood asthma in Seattle and the U.S., as well as the source of PAHs and mutagens in house dust. There is a need to use existing data to assess risks and set priorities for risk reduction. Perhaps the highest priority should be given to finding cost-effective methods of public education to reduce home exposures. Such methods may vary with the level of income and education. We recommend the following ... [Pg.72]

See other pages where Asthma cost-effectiveness is mentioned: [Pg.228]    [Pg.379]    [Pg.574]    [Pg.295]    [Pg.733]    [Pg.918]    [Pg.164]    [Pg.166]    [Pg.168]    [Pg.169]    [Pg.174]    [Pg.187]    [Pg.188]    [Pg.523]    [Pg.532]    [Pg.414]    [Pg.520]    [Pg.918]    [Pg.162]    [Pg.23]    [Pg.210]    [Pg.400]    [Pg.169]    [Pg.136]    [Pg.215]    [Pg.227]    [Pg.43]   
See also in sourсe #XX -- [ Pg.168 ]



SEARCH



Cost effectiveness

© 2024 chempedia.info